Assert-IQ vs Autoplaque
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your primary need is long-term, continuous monitoring for patients with suspected, infrequent, or transient heart rhythm disorders. This tool is ideal for comprehensive arrhythmia detection over several years, enabling remote management and proactive alerts for clinicians.
View Assert-IQ →Choose Autoplaque if…
Choose Autoplaque if you require AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This software is best suited for assessing a patient's heart attack risk and guiding treatment strategies based on detailed plaque characterization.
View Autoplaque →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Assert-IQ | Autoplaque |
|---|---|---|
| Deployment | Subcutaneously implanted device with mobile app connectivity | Workstation-based post-processing application, runs on Windows or Mac OS. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Assert-IQAssert-IQ offers a more integrated and less burdensome experience for both patients and clinicians. Its minimally invasive insertion, patient activator for symptom logging, and remote monitoring capabilities streamline data collection and patient engagement, contrasting with Autoplaque's workstation-based, clinician-intensive software interaction.
Clinical Value
TieBoth tools provide significant and distinct clinical value, each FDA-cleared for their respective applications. Assert-IQ excels in long-term arrhythmia diagnosis and management, while Autoplaque offers critical AI-powered quantitative analysis for coronary plaque and stenosis, aiding in heart attack risk prediction. Their value is high but in different cardiology sub-specialties.
Pricing & Value
TieNeither tool provides transparent pricing information in the structured facts or readily available online. Assert-IQ specifies 'enterprise' pricing, while Autoplaque's pricing is 'not disclosed.' Without specific cost details or demonstrable ROI, it is impossible to compare their value proposition.
Enterprise Readiness
Assert-IQAssert-IQ, backed by Abbott Medical, a global medical device company, explicitly states HIPAA compliance, offers hybrid deployment, and targets large health systems. Autoplaque, developed by a medical center, is workstation-based and does not specify HIPAA compliance or BAA, suggesting a potentially less mature enterprise integration model.
Innovation
AutoplaqueAutoplaque demonstrates greater innovation by leveraging AI for highly specialized quantitative analysis of coronary plaques and luminal stenoses from CT angiography, moving beyond traditional imaging interpretation for detailed risk prediction. While Assert-IQ offers advanced ICM features, Autoplaque's application of AI for complex plaque characterization represents a more novel diagnostic approach.
Support & Docs
Assert-IQAs a product from Abbott Medical, a large and established global medical device company, Assert-IQ is expected to have comprehensive and well-structured support and documentation resources. While Autoplaque is developed by a reputable medical center, its support infrastructure is likely less extensive and standardized compared to a major commercial entity.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | Autoplaque |
|---|---|---|
| Name | Assert-IQ | Autoplaque |
| Company | Abbott Medical | Cedars-Sinai Medical Center: AIM |
| Description | The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. |
| Tagline | Advanced, long-term insertable cardiac monitoring for comprehensive arrhythmia detection. | AI-Powered Quantitative Analysis for Coronary Plaque and Stenosis |
| Categories | Cardiology AI, Clinical Decision Support & Reference | Cardiology AI, Radiology & Imaging AI |
| Key Features | Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion | AI-powered quantitative analysis of atherosclerotic plaque, Detection and characterization of coronary artery plaque, Measurement of luminal stenoses, Analysis of coronary anatomy and pathology from CT Angiographic images, Workstation-based post-processing application, Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician), Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views, Measurement of vessel diameter and area |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and Autoplaque.